Trade CureVac N.V. - CVAC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.25 |
| Open | 3.28 |
| 1-Year Change | -4.93% |
| Day's Range | 3.22 - 3.36 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 3.27 | -0.03 | -0.91% | 3.30 | 3.36 | 3.17 |
| Feb 20, 2025 | 3.25 | -0.11 | -3.27% | 3.36 | 3.42 | 3.24 |
| Feb 19, 2025 | 3.27 | -0.16 | -4.66% | 3.43 | 3.46 | 3.25 |
| Feb 18, 2025 | 3.49 | 0.00 | 0.00% | 3.49 | 3.58 | 3.41 |
| Feb 14, 2025 | 3.63 | 0.01 | 0.28% | 3.62 | 3.66 | 3.51 |
| Feb 13, 2025 | 3.62 | -0.01 | -0.28% | 3.63 | 3.70 | 3.59 |
| Feb 12, 2025 | 3.64 | 0.16 | 4.60% | 3.48 | 3.68 | 3.48 |
| Feb 11, 2025 | 3.51 | -0.14 | -3.84% | 3.65 | 3.67 | 3.50 |
| Feb 10, 2025 | 3.68 | -0.13 | -3.41% | 3.81 | 3.82 | 3.54 |
| Feb 7, 2025 | 3.57 | -0.08 | -2.19% | 3.65 | 3.73 | 3.56 |
| Feb 6, 2025 | 3.71 | -0.12 | -3.13% | 3.83 | 3.93 | 3.70 |
| Feb 5, 2025 | 3.76 | 0.17 | 4.74% | 3.59 | 3.76 | 3.56 |
| Feb 4, 2025 | 3.58 | 0.07 | 1.99% | 3.51 | 3.60 | 3.47 |
| Feb 3, 2025 | 3.52 | -0.06 | -1.68% | 3.58 | 3.67 | 3.49 |
| Jan 31, 2025 | 3.74 | -0.10 | -2.60% | 3.84 | 3.86 | 3.69 |
| Jan 30, 2025 | 3.81 | -0.02 | -0.52% | 3.83 | 3.92 | 3.79 |
| Jan 29, 2025 | 3.86 | -0.03 | -0.77% | 3.89 | 4.07 | 3.84 |
| Jan 28, 2025 | 3.99 | 0.27 | 7.26% | 3.72 | 4.01 | 3.68 |
| Jan 27, 2025 | 3.76 | -0.01 | -0.27% | 3.77 | 3.88 | 3.67 |
| Jan 24, 2025 | 3.82 | -0.13 | -3.29% | 3.95 | 4.05 | 3.79 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CureVac N.V. Company profile
CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).
The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’
CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.
The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.
CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.
According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.
According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.
You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.
| Industry: | Biotechnology & Medical Research (NEC) |
Friedrich-Miescher-Str. 15
TUEBINGEN
BADEN-WUERTTEMBERG 72076
DE
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com